Abstract 141P
Background
This study describes the real-world prescribing patterns, effectiveness, and tolerability of cabozantinib in patients in Taiwan with advanced renal cell carcinoma (aRCC) that progressed despite prior antiangiogenic therapy.
Methods
This retrospective cohort study used clinical records from seven hospitals in Taiwan (October 2018–quarter 4 2020). Adults (aged ≥ 20 years, living or deceased) who had received at least one dose of cabozantinib for aRCC after at least one prior antiangiogenic therapy enrolled. Participants were characterized at baseline, and cabozantinib use (dose, treatment line, prior therapies), effectiveness (objective response rate [ORR], progression-free survival [PFS]) and tolerability (adverse events [AEs]) were described.
Results
In total, 51 patients enrolled (Table). Cabozantinib was 2L therapy for 20 patients (39%), 3L for 17 (33%) and 4+L for 14 (27%). The most common prior therapies were sunitinib and pazopanib. Seven patients (14%; 2L, 1; 3L, 3; 4+L, 3) received cabozantinib combined with another therapy. Initial cabozantinib dose was 60 mg/day for 57% of patients and 40 mg/day for 33%; of these, 72% and 12%, respectively, had a dose reduction. Treatment was interrupted for 26% of patients and discontinued for 49%. During a median treatment duration of 9.7 (range, 3–29) months, mean daily cabozantinib dose was 44.4 mg. ORR was 39%; 20 patients had a partial response and 0 a complete response. Duration of response and PFS (median [95% CI]) were 9.5 (9.1, NE) and 12.4 (8.2, 16.3) months, respectively. The most common AEs were diarrhea (39% of patients) and palmar–plantar erythrodysesthesia (37%). Eleven patients (22%) had AEs of grade 3 or higher; four patients (8%) had serious AEs related to cabozantinib. One patient died due to an AE (consciousness disturbance not related to cabozantinib).
Conclusions
In this real-world study in Taiwan, cabozantinib prescribing patterns broadly aligned with the label. Outcomes were generally consistent with the pivotal, phase 3 METEOR trial. No new safety signals were found Table: 141P
2L cabozantinibN = 20 | 3L cabozantinibN = 17 | 4+L cabozantinibN = 14 | TotalN = 51 | |
Male, n (%) | 17 (85.0) | 14 (82.4) | 10 (71.4) | 41 (80.4) |
Agea, yrs, mean (SD) | 61.8 (10.4) | 59.4 (9.3) | 62.5 (11.4) | 61.2 (10.2) |
Metastatic RCCa, n (%) | 18 (90.0) | 16 (94.1) | 13 (92.9) | 47 (92.2) |
Clear cell RCC, n (%) | 15 (75.0) | 13 (76.5) | 13 (92.9) | 41 (80.4) |
Prior sunitinib, n (%) | 8 (40.0) | 13 (76.5) | 11 (78.6) | 32 (62.7) |
Prior pazopanib, n (%) | 11 (55.0) | 8 (47.1) | 8 (57.1) | 27 (52.9) |
Cabozantinib dose, mg/day, mean (SD) | 47.3 (10.4) | 39.9 (9.5) | 45.7 (10.4) | 44.4 (10.4) |
Cabozantinib treatment duration, months, median (range) | 10.5 (3–29) | 9.5 (3–15) | 8.8 (3–29) | 9.7 (3–29) |
Objective response rate, % | 55.0 | 23.5 | 35.7 | 39.2 |
aAt cabozantinib initiation.
.Clinical trial identification
Editorial acknowledgement
Dr Ruth Gandolfo of Oxford PharmaGenesis, Oxford, UK, provided medical writing and editorial support, which was sponsored by Ipsen, in accordance with Good Publication Practice guidelines.
Legal entity responsible for the study
Ipsen.
Funding
Ipsen.
Disclosure
Y. Tsai: Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Invited Speaker: Ipsen. J. Guo: Financial Interests, Personal, Speaker’s Bureau, Honoraria: Ipsen. E. Wang, V. Perrot: Financial Interests, Personal, Full or part-time Employment: Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides